AMANDA AYDIN: Open Payments
NPI 1821363144 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$339 in 17 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $46 · 2025 $339
Food & beverage: $339
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 2 | $52 |
| Astellas Pharma US Inc | 2 | $42 |
| ABBVIE INC. | 2 | $41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| TOLMAR, INC. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: REXULTI, Veozah, UBRELVY, JARDIANCE, NURTEC ODT, GEMTESA, GARDASIL 9, PAXLOVID.
Industry payments across NV — which companies pay providers there.
